Pentoxifylline reverses oxidative mitochondrial defect in claudicating skeletal muscle

Iraklis I Pipinos, Michael D. Boska, Alexander D. Shepard, Petros V. Anagnostopoulos, Asterios Katsamouris

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objective. Previous morphologic studies and phosphorus nuclear magnetic resonance spectroscopy (31P MRS) have suggested a primary mitochondrial defect in claudicating skeletal muscle. We hypothesized that pentoxifylline may alleviate this defect. Methods. The response of calf muscle bioenergetics to pentoxifylline was evaluated in 10 male, nondiabetic claudicants with 31P MRS and standard treadmill testing before and after 12 weeks of pentoxifylline therapy. Phosphocreatine (PCr) and adenosino-diphosphate (ADP) recovery rate constants, two very sensitive measures of oxidative mitochondrial function, were measured. Results. Seven of the 10 subjects had abnormal baseline PCr (<0.015 s-1) and ADP (<0.024 s-1) recovery rate constants. These 7 had significant improvement in mitochondrial function with pentoxifylline; their PCr recovery rate constants increased from 0.009 ± 0.002 to 0.013 ± 0.002 s-1 (P = 0.013) and their ADP recovery rate constants increased from 0.015 ± 0.002 to 0.022 ± 0.002 s-1 (P = 0.004). The remaining 3 patients had normal baseline constants and demonstrated no improvement after pentoxifylline therapy. Baseline PCr and ADP recovery rate constants inversely correlated with their corresponding percentage of improvement after pentoxifylline (P < 0.05). In addition the percentage of improvement in the PCr and ADP recovery rate constants correlated with the percentage of improvement in initial claudication distance and maximum walking capacity (P < 0.05). Conclusions. Pentoxifylline improves the mitochondriopathy of claudicating muscle, producing the most improvement in limbs with the worse baseline mitochondrial function. These results point to a potential new mode of action for pentoxifylline in the treatment of claudication and identify a subgroup of patients with the best potential for improvement with treatment.

Original languageEnglish (US)
Pages (from-to)126-132
Number of pages7
JournalJournal of Surgical Research
Volume102
Issue number2
DOIs
StatePublished - Jan 1 2002

Fingerprint

Pentoxifylline
Skeletal Muscle
Phosphocreatine
Diphosphates
Muscles
Therapeutics
Phosphorus
Energy Metabolism
Walking
Magnetic Resonance Spectroscopy
Extremities

ASJC Scopus subject areas

  • Surgery

Cite this

Pentoxifylline reverses oxidative mitochondrial defect in claudicating skeletal muscle. / Pipinos, Iraklis I; Boska, Michael D.; Shepard, Alexander D.; Anagnostopoulos, Petros V.; Katsamouris, Asterios.

In: Journal of Surgical Research, Vol. 102, No. 2, 01.01.2002, p. 126-132.

Research output: Contribution to journalArticle

Pipinos, Iraklis I ; Boska, Michael D. ; Shepard, Alexander D. ; Anagnostopoulos, Petros V. ; Katsamouris, Asterios. / Pentoxifylline reverses oxidative mitochondrial defect in claudicating skeletal muscle. In: Journal of Surgical Research. 2002 ; Vol. 102, No. 2. pp. 126-132.
@article{9e09996ce129480fbbb149aee5022070,
title = "Pentoxifylline reverses oxidative mitochondrial defect in claudicating skeletal muscle",
abstract = "Objective. Previous morphologic studies and phosphorus nuclear magnetic resonance spectroscopy (31P MRS) have suggested a primary mitochondrial defect in claudicating skeletal muscle. We hypothesized that pentoxifylline may alleviate this defect. Methods. The response of calf muscle bioenergetics to pentoxifylline was evaluated in 10 male, nondiabetic claudicants with 31P MRS and standard treadmill testing before and after 12 weeks of pentoxifylline therapy. Phosphocreatine (PCr) and adenosino-diphosphate (ADP) recovery rate constants, two very sensitive measures of oxidative mitochondrial function, were measured. Results. Seven of the 10 subjects had abnormal baseline PCr (<0.015 s-1) and ADP (<0.024 s-1) recovery rate constants. These 7 had significant improvement in mitochondrial function with pentoxifylline; their PCr recovery rate constants increased from 0.009 ± 0.002 to 0.013 ± 0.002 s-1 (P = 0.013) and their ADP recovery rate constants increased from 0.015 ± 0.002 to 0.022 ± 0.002 s-1 (P = 0.004). The remaining 3 patients had normal baseline constants and demonstrated no improvement after pentoxifylline therapy. Baseline PCr and ADP recovery rate constants inversely correlated with their corresponding percentage of improvement after pentoxifylline (P < 0.05). In addition the percentage of improvement in the PCr and ADP recovery rate constants correlated with the percentage of improvement in initial claudication distance and maximum walking capacity (P < 0.05). Conclusions. Pentoxifylline improves the mitochondriopathy of claudicating muscle, producing the most improvement in limbs with the worse baseline mitochondrial function. These results point to a potential new mode of action for pentoxifylline in the treatment of claudication and identify a subgroup of patients with the best potential for improvement with treatment.",
author = "Pipinos, {Iraklis I} and Boska, {Michael D.} and Shepard, {Alexander D.} and Anagnostopoulos, {Petros V.} and Asterios Katsamouris",
year = "2002",
month = "1",
day = "1",
doi = "10.1006/jsre.2001.6292",
language = "English (US)",
volume = "102",
pages = "126--132",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Pentoxifylline reverses oxidative mitochondrial defect in claudicating skeletal muscle

AU - Pipinos, Iraklis I

AU - Boska, Michael D.

AU - Shepard, Alexander D.

AU - Anagnostopoulos, Petros V.

AU - Katsamouris, Asterios

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Objective. Previous morphologic studies and phosphorus nuclear magnetic resonance spectroscopy (31P MRS) have suggested a primary mitochondrial defect in claudicating skeletal muscle. We hypothesized that pentoxifylline may alleviate this defect. Methods. The response of calf muscle bioenergetics to pentoxifylline was evaluated in 10 male, nondiabetic claudicants with 31P MRS and standard treadmill testing before and after 12 weeks of pentoxifylline therapy. Phosphocreatine (PCr) and adenosino-diphosphate (ADP) recovery rate constants, two very sensitive measures of oxidative mitochondrial function, were measured. Results. Seven of the 10 subjects had abnormal baseline PCr (<0.015 s-1) and ADP (<0.024 s-1) recovery rate constants. These 7 had significant improvement in mitochondrial function with pentoxifylline; their PCr recovery rate constants increased from 0.009 ± 0.002 to 0.013 ± 0.002 s-1 (P = 0.013) and their ADP recovery rate constants increased from 0.015 ± 0.002 to 0.022 ± 0.002 s-1 (P = 0.004). The remaining 3 patients had normal baseline constants and demonstrated no improvement after pentoxifylline therapy. Baseline PCr and ADP recovery rate constants inversely correlated with their corresponding percentage of improvement after pentoxifylline (P < 0.05). In addition the percentage of improvement in the PCr and ADP recovery rate constants correlated with the percentage of improvement in initial claudication distance and maximum walking capacity (P < 0.05). Conclusions. Pentoxifylline improves the mitochondriopathy of claudicating muscle, producing the most improvement in limbs with the worse baseline mitochondrial function. These results point to a potential new mode of action for pentoxifylline in the treatment of claudication and identify a subgroup of patients with the best potential for improvement with treatment.

AB - Objective. Previous morphologic studies and phosphorus nuclear magnetic resonance spectroscopy (31P MRS) have suggested a primary mitochondrial defect in claudicating skeletal muscle. We hypothesized that pentoxifylline may alleviate this defect. Methods. The response of calf muscle bioenergetics to pentoxifylline was evaluated in 10 male, nondiabetic claudicants with 31P MRS and standard treadmill testing before and after 12 weeks of pentoxifylline therapy. Phosphocreatine (PCr) and adenosino-diphosphate (ADP) recovery rate constants, two very sensitive measures of oxidative mitochondrial function, were measured. Results. Seven of the 10 subjects had abnormal baseline PCr (<0.015 s-1) and ADP (<0.024 s-1) recovery rate constants. These 7 had significant improvement in mitochondrial function with pentoxifylline; their PCr recovery rate constants increased from 0.009 ± 0.002 to 0.013 ± 0.002 s-1 (P = 0.013) and their ADP recovery rate constants increased from 0.015 ± 0.002 to 0.022 ± 0.002 s-1 (P = 0.004). The remaining 3 patients had normal baseline constants and demonstrated no improvement after pentoxifylline therapy. Baseline PCr and ADP recovery rate constants inversely correlated with their corresponding percentage of improvement after pentoxifylline (P < 0.05). In addition the percentage of improvement in the PCr and ADP recovery rate constants correlated with the percentage of improvement in initial claudication distance and maximum walking capacity (P < 0.05). Conclusions. Pentoxifylline improves the mitochondriopathy of claudicating muscle, producing the most improvement in limbs with the worse baseline mitochondrial function. These results point to a potential new mode of action for pentoxifylline in the treatment of claudication and identify a subgroup of patients with the best potential for improvement with treatment.

UR - http://www.scopus.com/inward/record.url?scp=0036353399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036353399&partnerID=8YFLogxK

U2 - 10.1006/jsre.2001.6292

DO - 10.1006/jsre.2001.6292

M3 - Article

VL - 102

SP - 126

EP - 132

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 2

ER -